Metastatic Melanoma Patient-derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

PURPOSE: Over 60 % of melanoma patients respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on BRAF mutation status, but no available agents are available for NRAS, NF1, CDKN2A, PTEN, and TP53 mutations. Over...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Shattuck-Brandt, Rebecca L., Chen, Sheau-Chiann, Murray, Emily, Johnson, C. Andrew, Crandall, Holly, O’Neal, Jamye F., Al-rohil, Rami Nayef, Nebhan, Caroline A., Bharti, Vijaya, Dahlman, Kimberly B., Ayers, Gregory D., Kelley, Mark, Kauffmann, Rondi M., Hooks, Mary, Grau, Ana, Johnson, Douglas B., Vilgelm, Anna E., Richmond, Ann
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367743/
https://ncbi.nlm.nih.gov/pubmed/32234759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1895
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker